Teva, Sanofi score well with anti-TL1A drug in IBD test
The TL1A drug would serve as a companion to Sanofi and partner Regeneron's multibillion-dollar blockbuster Dupixent (dupilumab), which is approved across several indications, including atopic dermatitis, and is also in clinical testing for UC. Sanofi meanwhile also has a RIPK1 inhibitor, eclitasertib, in phase 2 for UC.
Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 ...
As Merck and Roche continue to march their respective inflammatory bowel disease (IBD) assets through the clinic, Sanofi and ...
GlobalData on MSN1d
Sanofi and Teva’s duvakitug meets primary endpoints in Phase IIb trialSanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody ...
Sanofi & Teva Pharma’s RELIEVE UCCD phase 2b study of duvakitug in ulcerative colitis and Crohn’s disease meets primary endpoints: Paris Thursday, December 19, 2024, 11:00 Hrs ...
Phase 2 results in inflammatory bowel disease hinted the therapy could be more potent than similar medicines from Merck and ...
Teva reported that the trial met its primary endpoints in ulcerative colitis and Crohn's disease, the most common forms of ...
Sanofi (SNY) and Teva Pharmaceuticals (TEVA) announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback